ScholarIQanswers from OpenAlex & ORCID
Thomas John
ResearcherPublications, citations & collaboration network
Thomas John is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Thomas John have?
ScholarIQindexed works
Thomas John has 452 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Thomas John have?
ScholarIQcitation count
Thomas John has 19,369 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Thomas John?
ScholarIQh-index
Thomas John has an h-index of 57 in OpenAlex.
What is the i10-index of Thomas John?
ScholarIQi10-index
Thomas John has an i10-index of 168 in OpenAlex.
What is the ORCID of Thomas John?
ScholarIQorcid
The ORCID for Thomas John is on the source record.
What is the OpenAlex record for Thomas John?
ScholarIQopenalex
The OpenAlex for Thomas John is on the source record.
What are the most-cited papers on Thomas John?
ScholarIQmost cited works
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Salvatore Siena, Alice T. Shaw, Anna F. Farago, Collin M. Blakely, Takashi Seto, Byoung Chul Cho, Diégo Tosi, Benjamin Besse, Sant P. Chawla, Lyudmila Bazhenova, John C. Krauss, Young Kwang Chae, Minal Barve, Ignacio Garrido‐Laguna, Stephen V. Liu, Paul Conkling, Thomas John, Marwan Fakih, Darren Sigal, Herbert H. Loong, Gary L. Buchschacher, Pilar Garrido, Jorgé Nieva, Conor Steuer, Tobias R. Overbeck, Daniel W. Bowles, Elizabeth Fox, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, George D. Demetri
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lü, Wu‐Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz M. Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi‐Long Wu
Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee, Takayasu Kurata, Dong‐Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov, Serban Ghiorghiu, Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, Kenneth S. Thress, Pasi A. Jänne